Matt Hoffman

An analysis of MSBase data including more than 14,000 patients with MS suggests that disease-modifying therapies are effective in improving disability outcomes in relapsing disease.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Leigh Charvet, PhD.

Increasing the use and accessibility of mechanical thrombectomy may reduce the burden of stroke on a global scale.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Frontera, MD, and a number of others.

In a NeurologyLive® Peer Exchange, a panel of migraine specialists discussed the novel therapies in development and those entering the market for the treatment of acute migraine.

The Merz Therapeutics product, marketed as Xeomin, is the first and only FDA-approved neuromodulator available for patients aged 2 years and older with chronic sialorrhea.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive look into the discussion surrounding aducanumab and how it reflects the challenges of conducting clinical trials in Alzheimer disease.

Treating Alzheimer disease presents a spiderweb of complexity for physicians, and its intricacies have made assessing therapies equally puzzling.

After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.

Pimavanserin (Nuplazid; Acadia) is indicated for hallucinations and delusions associated with Parkinson disease psychosis, and the capsules can now be emptied onto food for patients with swallowing issues.

Further results of the 2 phase 3 studies are expected to be completed and presented in detail in first half of 2021, with a BLA submission to follow.

Study data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry suggest that nonwhite children and infants have rates of SUDEP mortality 1.5 times higher than whites.

Interim data from a real-world study suggest that adjunctive treatment with brivaracetam is well-tolerated and may improve quality of life over 12 months for those with focal seizures.

The GW Pharmaceuticals product has shown confirmed efficacy in LGS, though the study failed to produce a firm conclusion regarding its efficacy in other drug-resistant epilepsies.

Zogenix’s fenfluramine (Fintepla) appears to provide durable and profound reductions in monthly convulsive seizure frequency for those with Dravet syndrome out to 3 years.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Merle Diamond, MD.

Study author Luc Evers and coauthor Bastiaan R. Bloem, MD, PhD, FRCPE, offer insight into the findings of a recent study assessing early treatment in PD.

New analyses from the phase 2b SPRINT-MS trial suggest that MediciNova’s ibudilast (also known as MN-166), can lessen retinal thinning as measured by optical coherence tomography.

Two experts in neuro-ophthalmology discuss the advances in the identification and treatment of patients presenting with optic neuritis.

As the adoption of telemedicine rises, the ability to incorporate digital and telehealth-based therapies offers clinicians a unique opportunity to supplement the comprehensive care model.

Ronald Crystal, MD, chairman, Department of Genetic Medicine, Weill Cornell Medicine, discussed the promise of gene therapy for patients with Alzheimer disease and related disorders.

After the 12-month open-label period, those treated with patisiran from the phase 3 APOLLO and phase 2 open-label parent studies maintained their improvements on the modified Neuropathy Impairment Score +7.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Paul Fisher, MD, and Gerald Grant, MD, FACS.

The NDA is supported by the phase 3 STOP 301 trial, which included more than 5650 migraine attacks in patients with or without aura.

This latest FDA indication includes adjunctive therapy for those aged 4 years and older in both the CV and intravenous formulations of the UCB product.

Jacqueline French, MD, director, Translational Research and Clinical Trials in Epilepsy, NYU Grossman School of Medicine, spoke to the takeaways of a recent study of nonmotor seizures.

Jacqueline French, MD, director, Translational Research and Clinical Trials in Epilepsy, NYU Grossman School of Medicine, discussed the need to improve early identification of patients with focal epilepsy.

Compared to other forms of CBT, pharmacotherapy, and no treatment, digital CBT offered a more than $640 net positive benefit in 94.7% of Markov model simulations.

Only small, nonsignificant improvements were observed in Unified Parkinson’s Disease Rating Scale motor scores, though the investigators did not report disease worsening with early treatment.

Leigh Charvet, PhD, discusses the adoption and potential of validated digital and tele-based approaches for the treatment of multiple sclerosis.